key: cord-0698692-tonemvd7 authors: Levytska, Khrystyna; Temming, Lorene; Dranove, Jason; Connors, Ngina; Pollack, Rebecca title: Multisystem inflammatory syndrome in children (MIS-C) in pregnancy can mimic new-onset pre-eclampsia: A case report date: 2022-05-10 journal: Case Rep Womens Health DOI: 10.1016/j.crwh.2022.e00420 sha: bb9e13df42472960fe300da690b758c341f06472 doc_id: 698692 cord_uid: tonemvd7 INTRODUCTION: Pregnant women affected by coronavirus disease 2019 (COVID-19) are at increased risk of severe disease, admission to an intensive care unit, and adverse pregnancy outcomes. In contrast, children typically experience a mild form of COVID-19. Nonetheless, there is a risk of multisystem inflammatory syndrome in children (MIS-C) following a SARS-CoV-2 infection. CASE: A healthy 16-year-old, G1P0, presented with MIS-C in the second trimester and was treated with intravenous immunoglobulin. She subsequently developed transient mild hypertension, proteinuria, and transaminitis, which ultimately was thought to be secondary to MIS-C rather than pre-eclampsia. DISCUSSION: MIS-C is an important COVID-19 complication in pediatric patients. This case offers guidance on expectant management of hypertension, transaminitis, and proteinuria during an episode of MIS-C in pregnant patients, as opposed to preterm delivery for a misdiagnosis of severe pre-eclampsia. Introduction requirement for mechanical ventilation or extracorporeal membrane oxygenation, and adverse pregnancy outcomes 2 . The proportion of cases of SARS-CoV-2 infections in children approaches 5%, with the 15-17-year age group comprising a third of infections; this includes reproductive-age adolescents who may become pregnant 3, 4 . Fortunately, pediatric cases rarely require admission to the pediatric intensive care unit (PICU) 4 . Although acute COVID-19 episodes in children are usually mild, recent evidence has shown that children may suffer a complication of COVID-19 characterized by a widespread inflammatory response first identified in April 2020 5 . This systemic response has been termed the multisystem inflammatory syndrome in children (MIS-C), defined as serious illness leading to hospitalization in patients under 21 years of age, with persistent fever, laboratory evidence of inflammation, multisystem (≥2) organ involvement, and current or recent SARS-CoV-2 infection or COVID-19 exposure within 4 weeks prior to onset of symptoms, without any alternative diagnoses 6, 7 . The characteristics of MIS-C have been described in detail in large patient populations 6 . The temporal relationship between the symptom onset and hospitalization for MIS-C is approximately 25 days. Almost a third of patients test negative for SARS-CoV-2 infection at the time of MIS-C diagnosis, but do have detectable antibodies. Most patients present with tachycardia, tachypnea, gastrointestinal symptoms, rash, and conjunctival injection, and all patients present with fever. Those with worse symptoms have elevated levels of C-reactive protein (CRP), D-dimer, erythrocyte sedimentation rate (ESR), ferritin, troponin, cardiac b-type natriuretic peptide (BNP), liver enzymes, and others. They can also exhibit anemia, thrombocytopenia, and neutrophilia. The vast majority of MIS-C patients require admission to the ICU and 62% receive vasopressor support, with a median length of hospital stay of 6 days. Most patients affected by MIS-C are treated with intravenous (IV) immunoglobulin (IVIG) and almost half receive glucocorticosteroids 6 . Although the amount of data on MIS-C in the general pediatric population and data on COVID-19 in the adult pregnant population are growing, there is limited data on MIS-C in the pregnant pediatric population. To date, there are no published reports of MIS-C in pregnancy (according to a MEDLINE search with the following terms: "multi-system inflammatory syndrome children", "MIS-C", "pediatric multisystem inflammatory disease", "pregnant", "pregnancy", "pediatric(s)", "pediatric patient", "teen; teen pregnancy", and "juvenile; juvenile pregnancy"). This report describes management of a patient in her second trimester of pregnancy during an acute MIS-C episode. The patient was a previously healthy 16-year-old, G1P0, who presented to the Emergency Department (ED) at 25+2 weeks with fever, shortness of breath, and diarrhea. In the ED, she had an overall unremarkable work-up, including a negative COVID-19 test, although a computerized tomography (CT) angiogram showed bilateral pulmonary ground-glass opacities without evidence of pulmonary emboli. The patient had significant improvement of her symptoms with IV hydration and anti-pyrectics. Given complete resolution of her symptoms and stable vital signs, she was discharged home at that time with close follow-up, with a discharge diagnosis of upper respiratory infection and fever. She represented at 26+1 weeks' gestation with persistent fever and worsening shortness of breath. The patient was ill-appearing, tachypneic, tachycardic, and febrile. Although she continued to saturate well on room air without need for oxygen support (98-100% SpO2), her tachycardia reached a maximum of 140 bpm, fever peaked at 102.9 F, and she had low-normal blood pressure readings (ranging from systolic 105-132 mm Hg and diastolic 53- ng/mL]) 8 . Her renal and hepatic function tests were normal. A respiratory pathogen panel was sent and a chest X-ray was unremarkable. An echocardiogram showed normal ejection fraction, no wall motion abnormalities, normal coronary artery dimensions without evidence of aneurysms, and a trivial pericardial effusion. Fetal monitoring showed fetal tachycardia, minimal variability without accelerations or decelerations, and she exhibited uterine irritability on the tocometer. While in the ED, the patient's status worsened. She became increasingly hypotensive with systolic blood pressure readings ranging from 93 to 104 mmHg and diastolic from 41 to 57 mmHg, with mean arterial pressure (MAP) values dropping, ranging from 53 to 68 mmHg (normal range for second trimester: 77 ± 6 mmHg) 9 . This change in clinical status required initiation of pressor support with norepinephrine at an initial dose of 3 mcg/min, initiation of broad-spectrum IV antibiotics with ceftriaxone (2gm q24h) and vancomycin (loading dose 1,500mg) while blood and urine cultures were pending, and she was admitted to the PICU for further management. In the PICU, patient was continued on pressor support, and started on anticoagulation on admission (enoxaparin 0.5m/kg every 12 hours per institution protocol) as well as IV steroids (methylprednisolone 30mg twice daily). She was maintained on pressor support, reaching a maximum dose of norepinephrine 7 mcg/min at 24 hours The patient had spontaneous resolution of her mild hypertension and her LFTs continued to improve after peaking on HD 8 and 9. She was discharged on HD 13 with close follow-up with maternal-fetal medicine, infectious diseases, and pediatric cardiology. Fetal growth at time of hospitalization at 27+2 weeks showed an appropriately grown fetus measuring 992g (45%ile), with a normal fluid level. After discharge, the patient was followed weekly for laboratory studies and amniotic fluid index assessment, which showed complete resolution of transaminitis and she continued to have reassuring fetal assessments. Her proteinuria resolved by 3 weeks after discharge, as seen by a J o u r n a l P r e -p r o o f Journal Pre-proof follow-up 24-hour urine protein, which returned with 95mg. The patient completed her course of oral steroids ten days after discharge; her overall steroid administration included initial dexamethasone 6mg every 12 hours for two doses (chosen for fetal lung maturity in the event of need for early delivery and potential treatment of COVID-19), followed by methylprednisolone 30mg twice daily for 5 days (with overlapping 2 doses of betamethasone 12mg every 24 hours), followed by an oral prednisone taper (15mg every 12 hours for 5 days, then 15mg daily for 5 days). The patient was followed every 7-10 days in the clinic between 28 and 38 weeks with serial biophysical profiles and growth ultrasound scans. She was diagnosed with fetal growth restriction (FGR) at 33 weeks of gestation, with estimated fetal weight (EFW) 25% and abdominal circumference (AC) 7%, umbilical artery Doppler pulsatility index (PI) 90%ile. Her FGR persisted and she was, therefore, scheduled for induction of labor at 38 weeks. She delivered a healthy infant, weighing 2,535g (small for gestational age, 5%) via an uncomplicated vaginal delivery. Both mother and baby were doing well at the time of this report. Patient consent was obtained to describe the above findings in the case report in accordance with local legislation. In this report, we present a pediatric patient in the second trimester of pregnancy who developed MIS-C in the setting of a SARS-CoV-2 infection. She presented with significant multi-organ (cardiac, hematologic, hepatic, and renal) involvement, accompanied by markedly elevated inflammatory markers. Interestingly, during her stay she also developed mild hypertension, which temporally coincided with significant transaminitis and proteinuria. This was concerning for the development of pre-eclampsia with severe features. Transaminitis peaked on HD 8 and 9, then continued to improve and resolved completely by 3 weeks after onset. Her blood pressure returned to normal prior to discharge, and proteinuria completely resolved by 4 weeks after diagnosis. She proceeded to develop FGR in the third trimester, for which she was induced, and delivered a healthy neonate at term. The multi-organ involvement during MIS-C in setting of COVID-19 made the potential diagnosis of preeclampsia unclear and difficult to manage in this case. The patient had mild hypertension, proteinuria, and transaminitis, which created concern for development of pre-eclampsia with severe features, but it was suspected that 11 . These patients developed elevated blood pressure, a rise in LFTs to more than twice normal, and proteinuria to ≥300 mg/d; only one of 6 severe COVID-19 cases had an abnormal sFLT-1/PlGF (soluble fms-like tyrosine kinase-1 to placental growth factor) ratio and uterine artery dopplers, suggestive of placental insufficiency. This suggested that the physiologic changes during COVID-19 were not due to pre-eclampsia, which often does lead to placental dysfunction. The sFLT-1/PlGF ratio was not tested in our study because the facilities were not available. While the Medoza study offers potential strategies for diagnosing pre-eclampsia and HELLP in pregnancies affected with COVID-19, this study did not encompass pediatric patients with MIS-C. Acute hepatitis has been reported in patients affected by MIS-C. Cantor et al reviewed 44 cases of MIS-C and found that 43% of them had laboratory evidence of hepatitis, defined as elevation of ALT >40 [UI]/L and AST >50 [UI]/L 12 . Most commonly, liver enzymes were highest on admission (63% of patients); however, in the rest of the cases, they peaked on days 1 to 4 of hospitalization. Only 26% of the patients with hepatitis had confirmed evidence of SARS-CoV-2 infection. This supports our speculation that the transaminitis in our patient was secondary to MIS-C as opposed to pre-eclampsia, although the temporal relationship of the peak of transaminitis in our case was notably later (days 8 to 9). It is important to note that exclusion of acute hepatitis or auto-immune hepatitis does not exclude the diagnosis of pre-eclampsia in this case, but only assists with eliminating other causes of transaminitis. Our case can be used to offer guidance on expectant management of transaminitis and proteinuria in a pregnant pediatric patient with mild hypertension in the setting of MIS-C diagnosis. The case illustrates the complete resolution of these symptoms by 3-4 weeks after diagnosis. Management with a multi-disciplinary care team, including maternal-fetal medicine, pediatric gastroenterology, intensivists, and infectious diseases specialists, is critical to Coronavirus Resource Center JHUoM. COVID-19 Dashboard by the Center for Systems Science and Engineering Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status -United States COVID-19-Associated Multisystem Inflammatory Syndrome in Children -United States A Pediatric Infectious Diseases Perspective of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Novel Coronavirus Disease 2019 (COVID-19) in Children Hyperinflammatory shock in children during COVID-19 pandemic Multisystem Inflammatory Syndrome in U.S. Children and Adolescents Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Central haemodynamics in normal pregnancy: a prospective longitudinal study Pregnancy and COVID-19 Pre-eclampsia-like syndrome induced by severe COVID-19: a prospective observational study Acute Hepatitis Is a Prominent Presentation of the Multisystem Inflammatory Syndrome in Children: A Single-Center Circulating Angiogenic Factors and the Risk of Preeclampsia Diagnostic Accuracy of sFlt1/PlGF ratio as a marker for preeclampsia This article was not commissioned and was peer reviewed. The authors have no conflicts to disclose which could have inappropriately influenced this work.